Berk L, de Man R A, Housset C, Berthelot P, Schalm S W
Department of Internal Medicine II, University Hospital Rotterdam.
Prog Clin Biol Res. 1991;364:411-20.
Ten patients with chronic hepatitis type D were treated during 4 months with alpha lymphoblastoid interferon in combination with two 2-week courses of acyclovir. Median percentage of HDAg-positive hepatocytes decreased from 11 to 1, p = 0.0225. Patients with no liver HDAg expression after treatment (n = 5) showed improved AST levels (normal in 4) and diminished liver cell inflammation. One patient, who cleared HDAg has complete biochemical remission of his liver disease with 2 years of follow-up. Five patients with persistent, albeit low, HDAg expression in the liver, had continued liver cell destruction (AST elevated and/or abnormal biopsy). No evidence for an enhancing effect of acyclovir for interferon therapy was observed.
10例丁型慢性肝炎患者接受了4个月的α淋巴母细胞干扰素治疗，并联合两个为期2周的阿昔洛韦疗程。HDAg阳性肝细胞的中位百分比从11%降至1%，p = 0.0225。治疗后肝脏无HDAg表达的患者（n = 5）显示AST水平改善（4例正常）且肝细胞炎症减轻。1例清除HDAg的患者在2年随访中肝病获得完全生化缓解。5例肝脏中HDAg表达持续存在（尽管水平较低）的患者，肝细胞持续破坏（AST升高和/或活检异常）。未观察到阿昔洛韦对干扰素治疗有增强作用的证据。
